MD+DI has been following Eko's growth for years. In 2019, the company debuted its aortic stenosis (AS) detection algorithm at the American Society of Echocardiography 2019 Scientific Sessions, with a study at the time showing that Eko's solution was able to accurately detect AS. It later shared positive study result for its DUO digital stethoscope as a heart failure screening tool. The company then won FDA clearance for a suite of algorithms for its digital stethoscope to screen for heart conditions that include heart murmurs and atrial fibrillation (AFib) during routine physical exams.
Eko stepped up to support remote care during the COVID-19 pandemic, with its digital stethoscope and ECG live-streaming platform for video conferencing.
In a recent press release, Connor Landgraf, cofounder and CEO of Eko, said that "Eko has achieved numerous milestones over the past year, including doubling our clinician user base, developing novel machine learning technologies, and meeting clinical landmarks. Our team is proud to be recognized by Fast Company as one of the most innovative companies in the world. We are creating a new standard of cardiac care to ensure all patients have early access to heart and lung disease detection."